Advances and prospects of drug clinical research in colorectal cancer in 2022

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.

Cite

CITATION STYLE

APA

Su, D., Liu, C., Cui, J., Tang, J., Ruan, Y., & Zhang, Y. (2023, April 1). Advances and prospects of drug clinical research in colorectal cancer in 2022. Cancer Innovation. John Wiley and Sons Inc. https://doi.org/10.1002/cai2.62

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free